- Solid IXIARO®/JESPECT® sales revenues up by 36.4% to EUR 4.6m in Q1 2012 compared to Q1 2011
- Net loss reduced by 28.2% to EUR 8.1m; cash position of EUR 38.5m at quarter end
- Pseudomonas clinical Phase II/III study initiated - interim futility results expected mid 2013 - other R&D activities on track
For details please see the attached Q1 report.
We cordially invite you to listen to conference call via webcast:
Tuesday, May 8, 2012
2 p.m. CET (1 p.m. BST / 8 a.m. EST)
Chairperson: Thomas Lingelbach, CEO Intercell AG
If you have any further questions please do not hesitate to contact us.